SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

RecruitingOBSERVATIONAL
Enrollment

470

Participants

Timeline

Start Date

October 25, 2023

Primary Completion Date

December 30, 2030

Study Completion Date

December 30, 2030

Conditions
Non-small Cell Lung CancerColorectal CancerBreast Cancer
Interventions
DIAGNOSTIC_TEST

Guardant360

Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.

Trial Locations (1)

60077-1384

RECRUITING

Orchard Healthcare Research Inc., Skokie

Sponsors
All Listed Sponsors
lead

Guardant Health, Inc.

INDUSTRY